Cerebral astrocytoma
disease diseaseOn this page
Also known as astrocytoma (excluding glioblastoma) of cerebral hemisphereastrocytoma of cerebral hemispheresastrocytoma of cerebrumastrocytoma of the cerebral hemispheresastrocytoma of the cerebrumcerebral hemisphere astrocytoma (excluding glioblastoma)cerebral hemispheric astrocytoma
Summary
Cerebral astrocytoma (MONDO:0021633) is a disease and 1 clinical trial. Top therapeutic interventions include bevacizumab, temozolomide, and vorinostat. A subtype of neoplasm of cerebral hemisphere — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 1
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | cerebral astrocytoma |
| Mondo ID | MONDO:0021633 |
| NCIT | C4951 |
| SNOMED CT | 99131000119108 |
| UMLS | C0750935 |
| MedGen | 196691 |
| GARD | 0025342 |
| Anatomy (UBERON) | UBERON:0001869 |
| Is cancer (heuristic) | no |
Also known as: astrocytoma (excluding glioblastoma) of cerebral hemisphere · astrocytoma of cerebral hemispheres · astrocytoma of cerebrum · astrocytoma of the cerebral hemispheres · astrocytoma of the cerebrum · cerebral astrocytoma · cerebral hemisphere astrocytoma (excluding glioblastoma) · cerebral hemispheric astrocytoma
Disease family
This is a subtype of neoplasm of cerebral hemisphere. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › nervous system disorder › central nervous system disorder › brain disorder › brain neoplasm › neoplasm of cerebral hemisphere › cerebral astrocytoma
Related subtypes (6): frontal lobe neoplasm, cerebral hemisphere cancer, occipital lobe neoplasm, neoplasm of temporal lobe, neoplasm of parietal lobe, benign neoplasm of cerebrum
Subtypes (1): childhood cerebral astrocytoma
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 1.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE2/PHASE3 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT01236560 | PHASE2/PHASE3 | COMPLETED | Vorinostat, Temozolomide, or Bevacizumab in Combination With Radiation Therapy Followed by Bevacizumab and Temozolomide in Young Patients With Newly Diagnosed High-Grade Glioma |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| BEVACIZUMAB | 4 | 1 |
| TEMOZOLOMIDE | 4 | 1 |
| VORINOSTAT | 4 | 1 |
| CHEMBL4228794 | 0 | 1 |
| CHEMBL4248195 | 0 | 1 |
Related Atlas pages
- Drugs: Bevacizumab, Temozolomide, Vorinostat